# HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

> **NCT07462923** · PHASE1 · RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** HS-20093 for injection

## Key facts

- **NCT ID:** NCT07462923
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-29
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07462923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07462923, "HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07462923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*